Preventing heart damage from chemotherapy in lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy, Injuries & trauma clinical trials.
This trial tests if the drug dexrazoxane can protect the heart during chemotherapy for a type of lymphoma called DLBCL. It may be an option for patients starting a standard treatment regimen known as R-CHOP.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of one of these lymphomas: DLBCL, high-grade B-cell lymphoma, follicular lymphoma, or T-cell/histiocyte-rich B-cell lymphoma.
- You must be starting a treatment plan of 6 cycles of R-CHOP21 (with or without lenalidomide or extra rituximab).
- You must be at least 18 years old.
- Your cancer must be stage II, III, IV, or stage I with a large tumor (10 cm or more).
- You must have adequate organ function (heart, lungs, liver, kidneys) and not have certain other cancers or uncontrolled infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two different lengths of chemotherapy (4 cycles vs. 6 cycles) combined with two targeted drugs, polatuzumab vedotin and rituximab, for people with newly diagnosed DLBCL who have a low-risk score. The goal is to see if a shorter treatment works just as well with fewer side effects.
This trial tests if a heart-protecting drug (dexrazoxane) can prevent heart damage in people getting chemotherapy for certain types of large B-cell lymphoma. It is for patients who already have heart risk factors or a history of heart failure.
This Phase 2 study tests dexrazoxane, a heart-protecting medicine, to reduce heart side effects from chemotherapy in people with certain blood cancers. If you qualify, you would receive dexrazoxane along with chemotherapy, and the team will monitor your heart function closely.
This study tests dexrazoxane (DRZ) to see how it affects blood and heart-related “biomarkers,” or measurable signs of heart damage, after cancer treatment. It mainly targets survivors who may be at risk for cardiomyopathy (heart muscle weakness) or related heart failure.
This trial studies how to choose the safest and most effective radiation dose for diffuse large B-cell lymphoma (a type of non-Hodgkin lymphoma) after standard chemotherapy. It may help improve disease control while aiming to limit side effects from radiation.
This trial tests a higher dose of the targeted drug rituximab combined with standard chemotherapy (R-CHOP) for men with newly diagnosed, advanced DLBCL. The goal is to see if this stronger dose works better than the usual dose for this type of lymphoma.
Hear when a new DLBCL - Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.